Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on 50 States Today.
Press releases published on May 22, 2025
Helmet Mounted Display Market to Surge with 6.2% CAGR, Projected to Hit US$ 1,599.9 Million by 2035: Fact.MR Report
EIN Presswire
·
May 22, 2025
HMD market grows with rising demand for real-time awareness, hands-free use, and training tech across defense, aviation, and industry, says Fact.MR. ROCKVILLE, MD, UNITED STATES, May 22, 2025 /EINPresswire.com/ -- According to Fact.MR, a market research …
Actual SEO Media, Inc. Reveals Ways to Blend AI and Human Touch in Content Development
EIN Presswire
·
May 22, 2025
Actual SEO Media, Inc. encourages business owners to use AI and human skills. These tools can boost efficiency without sacrificing authenticity. HOUSTON, TX, UNITED STATES, May 22, 2025 /EINPresswire.com/ -- Artificial intelligence (AI) has made …
Commercial Drone Market Share and Growth Analysis: 20.8% CAGR Projected to Drive Market to USD 65.25 Billion by 2032
EIN Presswire
·
May 22, 2025
Key companies covered in the Commercial Drone Market are 3D Robotics, Inc., Aeronavics Ltd., AeroVironment Inc., Autel Robotics Holdings Limited, …
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
GlobeNewswire
·
May 22, 2025
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno’s Marketing Authorization …
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
GlobeNewswire
·
May 22, 2025
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, …
INDIGO Biosciences Launches Stable Reporter Cell Lines for Drug Discovery and Toxicology Research
EIN Presswire
·
May 22, 2025
STATE COLLEGE, PA, UNITED STATES, May 22, 2025 /EINPresswire.com/ -- INDIGO Biosciences, a global leader in cell-based assay solutions, announced today a significant expansion to its product portfolio with the launch of proprietary Stable Reporter Cell …
Univest Securities, LLC Announces Closing of $5 Million Registered Offering for its Client WORK Medical Technology Group LTD (NASDAQ: WOK)
GlobeNewswire
·
May 22, 2025
New York, New York, May 22, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered offering …
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 22, 2025
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd – – Encore presentation planned at EHA 2025 Congress – – Kura Oncology to host virtual investor event at 7:30pm …
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
May 22, 2025
Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune® HPV with pembrolizumab as 1L treatment of r/ …
RCF Opportunities Fund II L.P. Files Early Warning Report Regarding Common Shares of Defense Metals Corp.
GlobeNewswire
·
May 22, 2025
DENVER, May 22, 2025 (GLOBE NEWSWIRE) -- RCF Opportunities Fund II L.P. (“RCF”) reports that it has filed an early warning report under National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in respect …
IMUNON Announces Withdrawal of Form S-1 Registration Statement
GlobeNewswire
·
May 22, 2025
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and …
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
GlobeNewswire
·
May 22, 2025
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
Daktronics to Participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28th
GlobeNewswire
·
May 22, 2025
BROOKINGS, S.D., May 22, 2025 (GLOBE NEWSWIRE) -- Daktronics, Inc. (Nasdaq: DAKT), a leading global designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide today announced that Brad …
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
GlobeNewswire
·
May 22, 2025
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b …
ROHM Develops Compact Surface-Mount Near-Infrared LEDs Featuring Industry-Leading Radiant Intensity
GlobeNewswire
·
May 22, 2025
Santa Clara, CA and Kyoto, Japan, May 22, 2025 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced an expanded portfolio of surface-mount near-infrared (NIR) LEDs with new compact top-view types optimized for applications such as VR/AR devices, …
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
GlobeNewswire
·
May 22, 2025
Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. These data …
Lynch Carpenter Investigates Claims in Marlboro-Chesterfield Pathology Data Breach
GlobeNewswire
·
May 22, 2025
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Marlboro-Chesterfield Pathology (“MCP”) recently announced a cybersecurity incident, which impacted the personal information of thousands of individuals. The information potentially impacted in the data breach …
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 22, 2025
Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral presentation at the American Society of Clinical Oncology (ASCO) …
Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting
GlobeNewswire
·
May 22, 2025
AMSTERDAM, May 22, 2025 (GLOBE NEWSWIRE) -- Avidicure, a biotechnology company pioneering an entirely new dual agonistic, multifunctional antibody modality with broad applicability in oncology, today announced its upcoming presentation at the 2025 American …
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
GlobeNewswire
·
May 22, 2025
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …